Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) released its quarterly earnings results on Thursday, July, 27th. The company reported ($0.77) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.60. The company earned $15.10 million during the quarter, compared to analysts' expectations of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. Keryx Biopharmaceuticals's quarterly revenue was up 62.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.42) EPS. View Keryx Biopharmaceuticals' Earnings History.

Keryx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Keryx Biopharmaceuticals.

5 equities research analysts have issued twelve-month price targets for Keryx Biopharmaceuticals' shares. Their predictions range from $7.00 to $9.00. On average, they expect Keryx Biopharmaceuticals' share price to reach $7.50 in the next year. View Analyst Ratings for Keryx Biopharmaceuticals.

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:

• 1. According to Zacks Investment Research, "Keryx posted wider than expected loss in the second quarter of 2017 but sales exceeded expectations. The company is making efforts to expand the label of Auryxia. With Auryxia being the only approved product in Keryx’s portfolio, the company is entirely dependent on Auryxia for growth. Auryxia faces stiff competition in the U.S. from existing players, apart from over-the-counter drugs like some calcium carbonate and metal-based products. Apart from competition, Keryx may face strong pricing pressure for Auryxia. However, The  FDA accepted for review the supplemental New Drug Application (sNDA) for Auryxia tablets for the iron-deficiency anemia (IDA) indication and has set the Prescription Drug User Fee Act (PDUFA) target action date on Nov 6, 2017. A potential approval should increase sales. Shares of the company have outperformed the industry year to date." (9/14/2017)
• 2. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)

Keryx Biopharmaceuticals saw a decline in short interest during the month of August. As of August 15th, there was short interest totalling 17,904,212 shares, a decline of 8.1% from the July 31st total of 19,485,853 shares. Based on an average trading volume of 865,374 shares, the days-to-cover ratio is currently 20.7 days. Currently, 15.2% of the shares of the stock are sold short.

Some companies that are related to Keryx Biopharmaceuticals include Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), MyoKardia (MYOK), Acceleron Pharma (XLRN), Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Athenex (ATNX), Omeros Corporation (OMER), Amarin Corporation PLC (AMRN) and Retrophin (RTRX).

Keryx Biopharmaceuticals' management team includes the folowing people:

• Michael W. Rogers, Chairman of the Board
• Gregory Paul Madison, Chief Executive Officer, Director
• Scott A. Holmes, Chief Financial Officer, Treasurer
• Christine A. Carberry, Chief Operating Officer
• Douglas M. Jermasek, Vice President of Marketing and Strategy
• Brian R. Adams, General Counsel, Secretary
• Lora Pike, Senior Director
• John F. Neylan, Chief Medical Officer
• Kevin J. Cameron, Independent Director
• Mark J. Enyedy, Independent Director

Keryx Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.06%), Abrams Capital Management L.P. (4.82%), State Street Corp (2.63%), FMR LLC (1.95%), Rice Hall James & Associates LLC (1.40%) and Ameriprise Financial Inc. (0.99%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes. View Institutional Ownership Trends for Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., State Street Corp, Iridian Asset Management LLC CT, Old West Investment Management LLC, California State Teachers Retirement System, Frontier Wealth Management LLC and Shufro Rose & Co. LLC. Company insiders that have sold Keryx Biopharmaceuticals stock in the last year include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes. View Insider Buying and Selling for Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Monarch Partners Asset Management LLC, Chicago Equity Partners LLC, Vanguard Group Inc., Rice Hall James & Associates LLC, Blair William & Co. IL, Sei Investments Co., Russell Investments Group Ltd. and Northern Trust Corp. View Insider Buying and Selling for Keryx Biopharmaceuticals.

Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $6.95.